On March 28-30, 2014, at the Arizona Biltmore Resort in Phoenix, AZ, ACMT held its 2014 Annual Scientific Meeting. The recorded lectures are featured below. All require registration to view but the lectures with the "Watch Now" button are provided complimentary. If you were a registered attendee at this conference, you can access these lectures by emailing videos@acmt.net and we will provide you a passcode.
The Use of Physostigmine by Toxicologists for Anticholinergic Toxicity
J. Wesley Watkins, MD, Washington University, St. Louis, MO
ACMT is pleased to share Dr. Watkins presentation which was awarded the Best Platform Presentation at the 2014 Annual Scientific Meeting.
Advanced Management Strategies for APAP Induced Fulminant Hepatic Failure
Ram Subramanian, MD, Emory University, Atlanta, GA
Objectives:
1. Describe the management of cerebral edema in APAP induced FHF.
2. Review the management of multi organ system dysfunction in APAP induced FHF.
3. Describe the role of Extracorporeal Liver Assist Devices in APAP Induced FHF.
Breakout Workshop C: Declaring Brain Death in the Toxicology Patient
Laura M. Tormoehlen, MD, Indiana University, Indianapolis, IN
Objectives:
1. Review brain death criteria
2. Discuss confirmatory neuroimaging in the diagnosis of brain death and the potential effects of drugs and toxins.
The Air Up There: Controversies Regarding the Toxicity of Aircraft Breathing Air
Michael J. Kosnett, MD, MPH, FACMT, University of Colorado, Denver, CO
1. Understand the basics of breathing air processing and flow aboard commercial passenger aircraft.
2. Learn the findings of investigations of health events possibly associated with travel on passenger aircraft.
3. Recognize current controversies regarding potential adverse health effects associated with aerosols in cabin air derived from aviation fluids and other aircraft components.
Advanced Neuroimaging and Toxicology
Laura M. Tormoehlen, MD, Indiana University, Indianapolis, IN
Objectives:
1. Discuss interpretation of MRI, specifically FLAIR and Diffusion-weighted imaging.
2. Review MR spectroscopy and its utilization in white matter disease, including toxic leukoencephalopathy.
3. Discuss SPECT imaging in idiopathic and drug induced parkinsonism.
Presidential Keynote: Specialty Toxicology Testing: The Interface with the Clinician and the Response to Emerging Drugs of Abuse
Robert Middleberg, PHD, DABFT, DABCC-T, Laboratory Director & Vice President, Quality Assurance, NMS Labs, Willow Grove, PA
Objectives:
1. Balancing the utility, practicality and the cost of specialty toxicology testing.
2. Development of novel assays: the role of the clinician and experience with synthetic cannabinoids.
Novel Applications of Mobile Technology to Measure and Change Behavior
Edward W. Boyer, MD, FACMT, University of Massachusetts, Worcester, MA
Objectives:
1. Develop an understanding of the range of mobile devices that can be used to measure behavior.
2. Develop an understanding of the range of mobile interventions that can be used to change behavior.
3. Develop an understanding of the methods to minimize engineer requirements for mobile interventions.
Toxicogenomics and Adverse Drug Reactions/Toxicity
Andrew Monte, MD, University of Colorado, Aurora, CO
Objectives:
1. Review polymorphisms associated with increased/decreased drug toxicity.
2. Review the limitations of toxicogenomics in predicting drug toxicity.
3. Discuss the future of translational toxicogenomics.
Hemodialysis: EXTRIP Updates
Paul I. Dargan, MBBS, FACMT, Guy's and St. Thomas' NHS Foundation Trust, London, UK
Objectives:
1. Discuss controversies in the use of dialysis for lithium toxicity.
2. Provide updates on the objectives and activities of the EXTRIP working group.
MENU
